Danco Laboratories, a manufacturer of the abortion pill mifepristone, told the Supreme Court on Tuesday that restricting use of the medication would cause “tremendous harm” to women.
The company petitioned the high court in September alongside the US Department of Justice to reverse a Fifth Circuit decision that would limit mifepristone’s use to conditions that existed before the FDA loosened some of its regulations in 2016 and 2021. Those changes have allowed the drug to be distributed by mail, lowered the requirement for in-person clinical visits, and extended how late into pregnancy a patient may take the drug from seven weeks to 10.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.